An analysis of the technologies behind last year’s biotech series A raisers finds clusters in mitophagy induction, epigenome editing and delivery vectors

BioCentury | Aug 7, 2023

Management Tracks

Khoo Shih named CEO of Singapore’s ClavystBio

Plus: New CEOs named at Vivoryon and Kytopen, and updates from Avalyn, Ankyra, Indaptus and more

BioCentury | Jun 29, 2023

Finance

Amy Schulman on the draw of Singapore, and more – The BioCentury Show

How Polaris views opportunity in Singapore, lessons from the funding environment, and women in leadership – is there progress?

BioCentury | Jun 13, 2023

Management Tracks

CEO Francis deSouza Illumina's second major departure in weeks

Plus: Denner among those departing Biogen’s board, and updates from the White House, Delix, Heron and more

BioCentury | Apr 25, 2023

Finance

Could Singapore become the next global biotech hub?

Local investors, global VCs aim to shape Singapore’s next biotechs

BioCentury | Mar 7, 2023

Product Development

Viehbacher’s vision, NK cells & bat biology

Takeaways from Biogen CEO’s conversation with BioCentury; plus, where things stand among NK cell companies and introducing newco Paratus

BioCentury | Feb 24, 2023

Emerging Company Profile

Paratus: leveraging bat biology to improve human health

Biotech has raised $100M to industrialize bat biology

Items per page:

1 - 8 of 8